|
O.A. Rubanenko, I.A. Zolotovskaya., P.R. Shatskaya
Modern methods of thrombosis prevention and treatment in cancer patients with atrial fibrillation: focus on apixaban
|
№7 / 2024
|
|
De V.A., Kochetkov A.I., Abdullaev Sh.P., Bochkov P.O., Klepikova M.V., Batyukina S.V., Mirzaev K.B., Ostroumova O.D.
On the possible relationship between polymorphic variants of the CYP2C19 gene, residual concentration and the presence of bleeding in patients who have suffered acute coronary syndrome and are receiving clopidogrel as part of dual antithrombotic therapy
|
№6 / 2024
|
|
Leonova M.V.
Antiarrhythmic effects of sodium-glucose cotransporter-2 inhibitors: a review of studies and mechanisms of action
|
№6 / 2024
|
|
Syrov A.V.
The use of propafenone in the treatment of atrial fibrillation
|
№6 / 2024
|
|
De V.A., Batyukina S.V., Kochetkov A.I., Klepikova M.V., Konik V.A., Ostroumova O.D.
Cognitive status of patients with coronary artery disease and concomitant atrial fibrillation
|
№4 / 2024
|
|
Kochetkov A.I., Telkova S.S., Dubinina A.V., Mirzaev K.B., Shastina V.R., Cherniaeva M.S., Dashabylova V.B., Ostroumova O.D.
Pharmacotherapy of elderly multimorbid patients with atrial fibrillation in real clinical practice: practical application of STOPP/START criteria
|
№4 / 2024
|
|
Sychev D.A., Cherniaeva M.S., Rozhkova M.A., Moiseeva E.A., Pogodina A.A., Bayzel Yu.S., Egorova L.A., Maslennikova O.M., Lomakin N.V.
Safety of direct oral anticoagulants in the treatment of atrial fibrillation in geriatric patients: focus on clinically relevant non-major bleeding
|
№4 / 2024
|
|
Leonova M.V.
Metformin prevents the development of atrial fibrillation
|
№2 / 2024
|
|
Orlova I.Yu., Batyukina S.V., Kochetkov A.I., Piksina G.F., Plotnikova N.A., Ostroumova O.D.
State of cognitive functions in patients with various forms of atrial fibrillation
|
№1 / 2024
|
|
Shatalova N.A., Mirzaev K.B., Abdullaev Sh.P., Sozaeva Zh.A., Bochkov P.O., Asoskova A.V., Denisenko N.P., Kochetkov A.I., Ebzeeva E.Yu., Chernyaeva M.S., Shastina V.R., Ostroumova O.D., Sychev D.A.
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease
|
№1 / 2024
|
|
A.V. Dubinina, A.I. Kochetkov, A.E. Vorobyova, S.S. Eremina, K.B. Mirzaev, O.D. Ostroumova
Analysis of the structure of comorbidities and pharmacotherapy in patients with a combination of atrial fibrillation and coronary heart disease
|
№14 / 2023
|
|
O.D. Ostroumova, A.V. Dubinina, V.A. De, A.I. Kochetkov, V.B. Dashabylova, S.S. Eremina, M.V. Klepikova
On the issue of improving the safety of antithrombotic therapy in patients with atrial fibrillation and coronary heart disease receiving antithrombotic therapy
|
№14 / 2023
|
Русский
